Igm Biosciences, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Baker Bros. Advisors LP and related entities report the disposition of all their shares in IGM Biosciences, Inc. following its acquisition by Concentra Biosciences, LLC.
IGM Biosciences, Inc. completed its merger with Concentra Biosciences, LLC, resulting in Redmile Group, LLC disposing of all its equity and warrant holdings.
IGM Biosciences Director Julie Hambleton reports the disposition of all common stock holdings following the company's merger into a wholly-owned subsidiary of Concentra Biosciences.
IGM Biosciences director Michael Lee reported the sale of 12,712 common shares following the company's merger with Concentra Biosciences, receiving $1.247 cash and a CVR per share.
Topsoe Holding A/S reports the disposition of its entire stake in IGM Biosciences, Inc. following the company's merger into a wholly-owned subsidiary of Concentra Biosciences, LLC.
IGM Biosciences, Inc. completed its merger with Concentra Biosciences, converting all outstanding shares into cash and contingent value rights.
IGM Biosciences, Inc. completed its merger with Concentra Biosciences, LLC, converting all shares into cash and contingent value rights.
A director of IGM Biosciences, Inc. reported the conversion of all common stock holdings into cash and contingent value rights following the company's merger with Concentra Biosciences, LLC.
IGM Biosciences, Inc. director William Strohl reported the conversion of his common stock holdings into cash and contingent value rights following the company's merger with Concentra Biosciences.
IGM Biosciences, Inc. completed its merger with Concentra Biosciences, converting shares and RSUs into cash and contingent value rights.
A director of IGM Biosciences, Inc. reported the disposition of all shares following the company's merger into a wholly-owned subsidiary of Concentra Biosciences, LLC.
IGM Biosciences' Chief Financial Officer, Misbah Tahir, sold 8,741 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
IGM Biosciences CEO Mary Beth Harler sold 14,501 shares of common stock at a weighted average price of $1.2728 to cover tax withholding obligations related to restricted stock unit vesting.
IGM Biosciences' Chief Business Officer, Lisa Lynn Decker, sold 4,409 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
IGM Biosciences, Inc. Director and 10% owner Jakob Haldor Topsoe acquired 828 shares of common stock on June 30, 2025, as part of a quarterly retainer in fully vested restricted stock units.
Form 4: IGM Biosciences Director Christina Topsoe Reports Acquisition of Vested Restricted Stock Units
Christina Teng Topsoe, a Director and 10% owner of IGM Biosciences, Inc., reported the acquisition of 1,284 shares of common stock through the vesting of restricted stock units as part of her director compensation.
IGM Biosciences, Inc. Director Elizabeth H.Z. Thompson acquired 694 shares of common stock on June 30, 2025, as part of her quarterly retainer, increasing her direct beneficial ownership to 7,196 shares.
Form 4: IGM Biosciences Director M. Kathleen Behrens Reports Acquisition of Shares Through Compensation Plan
IGM Biosciences Director M. Kathleen Behrens reported the acquisition of 1,471 shares of common stock as part of her quarterly retainer, increasing her total beneficial ownership to 382,535 shares.
Baker Bros. Advisors LP and affiliated entities reported that IGM Biosciences, Inc. director Felix J. Baker received 953 restricted stock units as compensation for his board service.
Form 4: IGM Biosciences Director Michael Lee Reports Acquisition of Common Stock as Quarterly Retainer
IGM Biosciences Director Michael Lee reported the acquisition of 828 shares of common stock as part of his quarterly retainer, with the shares held as a nominee for Redmile Group, LLC.
Redmile Group, LLC, a 10% owner and director of IGM Biosciences, Inc., acquired 828 shares of common stock through a restricted stock unit grant as part of director compensation.
Steven Weber, Principal Accounting Officer at IGM Biosciences, Inc., sold 486 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
IGM Biosciences, Inc.'s Chief Financial Officer, Misbah Tahir, sold 1,522 shares of common stock to satisfy tax withholding requirements related to restricted stock unit vesting.
IGM Biosciences, Inc. CEO Mary Beth Harler sold 1,522 shares of common stock to satisfy tax withholding requirements related to the vesting of restricted stock units.
Lisa Lynn Decker, Chief Business Officer of IGM Biosciences, Inc., sold 951 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
Steven Weber, Principal Accounting Officer of IGM Biosciences, sold 1,865 shares of common stock on May 14, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Director Michael Lee of IGM Biosciences reports the acquisition of 828 shares of common stock as a quarterly retainer, held on behalf of Redmile Group, LLC.
Redmile Group, through managing director Michael Lee's board service, acquired 828 restricted stock units of IGM Biosciences as part of director compensation.
Director Jakob Haldor Topsoe acquires 828 shares of IGM Biosciences common stock as part of a quarterly retainer, while Topsoe Holding A/S holds a significant indirect ownership.
Christina Teng Topsoe, a director of IGM Biosciences, reports acquiring shares through vested restricted stock units and indirect holdings through Topsoe Holding A/S and Pillarcater LLC.